News articles about Bristol-Myers Squibb (NYSE:BMY) have trended somewhat positive on Tuesday, Accern reports. Accern ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Bristol-Myers Squibb earned a news sentiment score of 0.21 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 46.2309431018007 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the headlines that may have impacted Accern Sentiment’s scoring:
- Judge cites SCOTUS’ Bristol-Myers decision to gut class action over Body Fortress dietary supplement (cookcountyrecord.com)
- Dowling & Yahnke LLC Boosts Position in Bristol-Myers Squibb Co (BMY) (tingoos.com)
- Bristol-Myers’ Yervoy receives EU approval to treat unresectable/metastatic melanoma in paediatric patients 12 years & above (pharmabiz.com)
- BRIEF-European Commission Approves Bristol-Myers Squibb’s Yervoy (reuters.com)
- Seattle Genetics' Adcetris Gets EU Nod for Label Expansion (finance.yahoo.com)
Several equities analysts have recently weighed in on BMY shares. Citigroup set a $72.00 price target on shares of Bristol-Myers Squibb and gave the stock a “buy” rating in a research note on Wednesday, October 25th. Jefferies Group reaffirmed a “buy” rating and set a $72.00 price target on shares of Bristol-Myers Squibb in a research note on Wednesday, September 27th. Vetr raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $66.50 target price for the company in a research note on Wednesday, September 27th. UBS Group reissued a “buy” rating and issued a $72.00 target price (up from $62.00) on shares of Bristol-Myers Squibb in a research note on Friday, October 6th. Finally, SunTrust Banks raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research note on Monday, October 30th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and nine have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $65.38.
Bristol-Myers Squibb (BMY) traded up $0.15 during trading hours on Tuesday, hitting $63.43. 5,889,284 shares of the company traded hands, compared to its average volume of 7,102,547. Bristol-Myers Squibb has a twelve month low of $46.01 and a twelve month high of $66.10. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.47. The company has a market capitalization of $103,820.00, a PE ratio of 24.97, a PEG ratio of 2.16 and a beta of 1.18.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.77 by ($0.02). Bristol-Myers Squibb had a net margin of 16.29% and a return on equity of 22.99%. The business had revenue of $5.25 billion for the quarter, compared to analyst estimates of $5.20 billion. During the same period in the prior year, the business earned $0.77 EPS. The company’s revenue for the quarter was up 6.7% compared to the same quarter last year. research analysts predict that Bristol-Myers Squibb will post 2.99 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, February 1st. Shareholders of record on Friday, January 5th will be issued a dividend of $0.40 per share. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. The ex-dividend date is Thursday, January 4th. This represents a $1.60 annualized dividend and a yield of 2.52%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 62.99%.
In other Bristol-Myers Squibb news, EVP Sandra Leung sold 156,582 shares of the firm’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $63.37, for a total transaction of $9,922,601.34. Following the completion of the sale, the executive vice president now owns 584,373 shares of the company’s stock, valued at approximately $37,031,717.01. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Thomas J. Jr. Lynch sold 5,300 shares of the firm’s stock in a transaction on Tuesday, December 12th. The shares were sold at an average price of $63.24, for a total value of $335,172.00. Following the sale, the executive vice president now directly owns 9,251 shares of the company’s stock, valued at approximately $585,033.24. The disclosure for this sale can be found here. Company insiders own 0.23% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Bristol-Myers Squibb (BMY) Share Price” was reported by TrueBlueTribune and is owned by of TrueBlueTribune. If you are accessing this story on another site, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this story can be viewed at https://www.truebluetribune.com/2018/01/23/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-bristol-myers-squibb-bmy-share-price.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.